Synthorx Inc (NASDAQ:THOR) Receives Consensus Rating of “Buy” from Brokerages

Synthorx Inc (NASDAQ:THOR) has received an average rating of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $25.50.

Several brokerages have recently issued reports on THOR. Zacks Investment Research downgraded shares of Synthorx from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. HC Wainwright set a $30.00 target price on shares of Synthorx and gave the company a “buy” rating in a research report on Wednesday, September 18th. Finally, ValuEngine downgraded shares of Synthorx from a “buy” rating to a “hold” rating in a research report on Wednesday, September 25th.

Shares of THOR stock traded up $0.08 during trading hours on Friday, hitting $13.18. 1,292 shares of the company were exchanged, compared to its average volume of 93,146. The business has a 50 day moving average of $17.29 and a two-hundred day moving average of $16.37. Synthorx has a 52 week low of $11.00 and a 52 week high of $23.53. The company has a market capitalization of $425.91 million and a PE ratio of -1.98.



Synthorx (NASDAQ:THOR) last issued its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.03). As a group, sell-side analysts forecast that Synthorx will post -1.81 earnings per share for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its position in Synthorx by 25.7% in the second quarter. BlackRock Inc. now owns 543,305 shares of the medical instruments supplier’s stock valued at $7,341,000 after purchasing an additional 111,165 shares in the last quarter. Vanguard Group Inc. grew its position in Synthorx by 8.4% in the second quarter. Vanguard Group Inc. now owns 336,963 shares of the medical instruments supplier’s stock valued at $4,552,000 after purchasing an additional 26,085 shares in the last quarter. Morgan Stanley grew its position in Synthorx by 9,312.2% in the second quarter. Morgan Stanley now owns 123,112 shares of the medical instruments supplier’s stock valued at $1,663,000 after purchasing an additional 121,804 shares in the last quarter. Northern Trust Corp grew its position in Synthorx by 1.6% in the second quarter. Northern Trust Corp now owns 92,542 shares of the medical instruments supplier’s stock valued at $1,251,000 after purchasing an additional 1,483 shares in the last quarter. Finally, Matisse Capital grew its position in Synthorx by 8.9% in the second quarter. Matisse Capital now owns 70,033 shares of the medical instruments supplier’s stock valued at $946,000 after purchasing an additional 5,700 shares in the last quarter. 65.62% of the stock is owned by institutional investors and hedge funds.

About Synthorx

Synthorx, Inc, a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor.

Recommended Story: CBOE Russell 2000® Volatility Index

Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.